Rheumatoid arthritis: guidelines for emerging therapies

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) causes significant individual and societal burdens.
• Current RA treatments, including anti-inflammatories and disease-modifying antirheumatic drugs (DMARDs), offer partial efficacy in preventing joint damage and functional decline.
• Emerging therapies like cytokine antagonists (anti-tumor necrosis factor) necessitate updated clinical guidelines.

Purpose of the Study:

• To review recent advancements in understanding rheumatoid arthritis.
• To discuss epidemiological characteristics, economic impact, clinical progression, and therapeutic options for RA.
• To propose pharmacologic utilization models and interim treatment guidelines.

Main Methods:

• Literature review of recent developments in rheumatoid arthritis.
• Analysis of epidemiological data, economic costs, and clinical progression.
• Evaluation of current and emerging RA therapies, including cytokine antagonists.
• Development of pharmacologic utilization models and suggested interim treatment guidelines.

Main Results:

• Rheumatoid arthritis has profound individual and societal impacts.
• Existing RA therapies provide limited success in halting disease progression.
• Novel anti-tumor necrosis factor therapies present new challenges and opportunities for RA management.
• A comprehensive review of RA's multifaceted aspects is presented.

Conclusions:

• The emergence of biologic therapies like anti-tumor necrosis factor agents requires adaptation of RA treatment strategies.
• Further research and consensus are needed for comprehensive RA treatment recommendations.
• Interim guidelines are proposed to aid clinicians and managed care organizations in managing rheumatoid arthritis effectively.
• Understanding RA's epidemiology, cost, progression, and therapies is crucial for optimal patient care.